U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07924852) titled 'Neuromodulation of Motivation and Reward Oscillations' on Oct. 26.
Brief Summary: Cannabis use disorder (CUD) and major depressive disorder (MDD) are among the most prevalent psychiatric conditions in the United States, affecting an estimated 20.6 million and 21 million adults respectively. Both disorders are characterized by anhedonia, diminished motivation, and blunted neural reward sensitivity. This shared dysregulated reward-processing may reflect a common prefrontal oscillatory dysfunction, centralized in mesolimbic dopaminergic reward pathways. This proposed project aims to investigate if transcranial alternating current (tACS...